wine and tirzepatide Alcohol: What Women Should Know Most Successful Weight Loss Program. Wine and Zepbound: Safety, Effects,

Eli Lilly has announced that it plans to submit Orforglipron to the FDA for regulatory review this year (2025) for weight loss, and in 2026 for type 2 diabetes

Of those who started GLP-1 therapy, 2.1% had a thyroid ultrasound performed at 1 year compared with 1.5% of those using a non-GLP-1 medication

Orforglipron tucks into a compact pocket in the upper helical bundle, contacting transmembrane helices 1, 2, 3, and 7 plus a key extracellular residue, and not engaging helices 4, 5, and 6 the way the peptide does

The FDA nod is based on the Phase III GENESIS trial, which compared Aphexda plus filgrastim against placebo plus filgrastim